BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05204237 (VK2735 in Weight Loss NASH): BVCT ex-ante prediction vs. reported outcome

On 16 Oct 2023, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 26 Mar 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT05204237
Drug Name
VK2735
Drug MoA
GLP1R/GIPR-biased dual agonist
Drug Modality
peptide drug
Drug Class
Best-In-Class
Therapeutic Area
Nutritional and Metabolic Diseases
Indication
Weight Loss NASH
Human Patients
136
Sponsor
Viking Therapeutics
Phase
Phase 1

Prediction of , index 476

Prospective Prediction
Prediction Index
476
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit superior to GSBR1289 and orforglipron)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
162 days in advance
Readout Data Interpretation
5.3% from baseline and 3.3% placebo-adjust weight reduction at 4 weeks vs 3% from baseline and 2% placebo-adjusted weight reduction for tirzepatide.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

No registry record was returned by the ClinicalTrials.gov API as of 2026-09-24.

NCT05204237 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials